Patents by Inventor Thomas Langguth
Thomas Langguth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116848Abstract: The present invention relates to a compound of formula (I) and an organic electronic device comprising a semiconductor layer which comprises a compound of formula (I).Type: ApplicationFiled: December 20, 2021Publication date: April 11, 2024Inventors: Benjamin Schulze, Max Peter Nüllen, Jakob Jacek Wudarczyk, Thomas Rosenow, Oliver Langguth, Regina Luschtinetz
-
Publication number: 20240121974Abstract: The present invention relates to a display device comprising a common charge generation layer and method for making the same.Type: ApplicationFiled: December 16, 2022Publication date: April 11, 2024Inventors: Oliver Langguth, Thomas Rosenow, Steffen Runge
-
Publication number: 20240107793Abstract: The present invention relates to an active-matrix OLED display, comprising a plurality of OLED pixels, wherein each pixel itself comprises a stack of organic layers and each layer of the stack of organic layers can form a common semiconductor layer, wherein—at least a first OLED pixel and a second OLED pixel comprising—an anode layer, —a common cathode layer, —at least a stack of organic layers, comprising a plurality of semiconductor layers.Type: ApplicationFiled: June 15, 2022Publication date: March 28, 2024Inventors: Oliver Langguth, Thomas Rosenow, Steffen Runge, Benjamin Schulze, Max Peter Nüllen, Jakob Jacek Wudarczyk, Vladimir Uvarov, Ulrich Heggemann, Steffen Willmann
-
Publication number: 20150335658Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: July 29, 2015Publication date: November 26, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jochen SCHUMACHER, Manfred SUESSE, Michael DITTGEN, Stephan MLETZKO, Jan-Peter INGWERSEN, Thomas LANGGUTH, Dirk SCHENK, Hubert KAFFL
-
Patent number: 9095691Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: March 15, 2013Date of Patent: August 4, 2015Assignee: Bayer Intellectual Property GmbHInventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Patent number: 9060955Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: GrantFiled: September 17, 2013Date of Patent: June 23, 2015Assignee: Bayer Intellectual Property GmbHInventors: Stefan Bracht, Ildiko Terebesi, Thomas Langguth
-
Publication number: 20150150827Abstract: The UV-stable solid transdermal therapeutic system (TTS) with UV absorber for photosensitive active pharmaceutical ingredients has a backing layer (1), at least one active ingredient-containing matrix (2), and a detachable protective film (3). Optionally an adhesive layer (4) and a separating layer (5) are introduced between the backing layer (1) and the at least one active ingredient-containing matrix (2). At least one hydroxyphenyltriazine compound acting as UV absorber is embedded in the backing layer (1), in the active it matrix (2), or in the adhesive layer (4). The TTS according to the invention achieves high stability at low concentrations of UV absorber, preferably 0.5 to 3% (m/m), so as to reduce or avoid skin irritation.Type: ApplicationFiled: January 28, 2015Publication date: June 4, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Thomas LANGGUTH, Stefan BRACHT
-
Patent number: 9005653Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 27, 2013Date of Patent: April 14, 2015Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Patent number: 8962013Abstract: The UV-stable solid transdermal therapeutic system (TTS) with UV absorber for photosensitive active pharmaceutical ingredients has a backing layer (1), at least one active ingredient-containing matrix (2), and a detachable protective film (3). Optionally an adhesive layer (4) and a separating layer (5) are introduced between the backing layer (1) and the at least one active ingredient-containing matrix (2). At least one hydroxyphenyltriazine compound acting as UV absorber is embedded in the backing layer (1), in the active ingredient-containing matrix (2), or in the adhesive layer (4). The TTS according to the invention achieves high stability at low concentrations of UV absorber, preferably 0.5 to 3% (m/m), so as to reduce or avoid skin irritation.Type: GrantFiled: May 2, 2006Date of Patent: February 24, 2015Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht
-
Publication number: 20140109916Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: Bayer Intellectual Property GmbHInventors: Thomas LANGGUTH, Stefan BRACHT, Michael DITTGEN, Petra HUBER, Dirk SCHENK
-
Patent number: 8668925Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 10, 2004Date of Patent: March 11, 2014Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Publication number: 20140018751Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicant: Bayer Intellectual Property GmbHInventors: Stefan BRACHT, lldiko TEREBESI, Thomas LANGGUTH
-
Patent number: 8557279Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: GrantFiled: September 6, 2011Date of Patent: October 15, 2013Assignee: Bayer Intellectual Property GmbHInventors: Stefan Bracht, Ildiko Terebesi, Thomas Langguth
-
Patent number: 8486443Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: February 4, 2004Date of Patent: July 16, 2013Assignee: Bayer IP GmbHInventors: Jochen Schuhmacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20120082714Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: ApplicationFiled: September 6, 2011Publication date: April 5, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Stefan BRACHT, Ildiko TEREBESI, Thomas LANGGUTH
-
Publication number: 20060251707Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: February 4, 2004Publication date: November 9, 2006Inventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20060246122Abstract: The UV-stable solid transdermal therapeutic system (TTS) with UV absorber for photosensitive active pharmaceutical ingredients has a backing layer (1), at least one active ingredient-containing matrix (2), and a detachable protective film (3). Optionally an adhesive layer (4) and a separating layer (5) are introduced between the backing layer (1) and the at least one active ingredient-containing matrix (2). At least one hydroxyphenyltriazine compound acting as UV absorber is embedded in the backing layer (1), in the active ingredient-containing matrix (2), or in the adhesive layer (4). The TTS according to the invention achieves high stability at low concentrations of UV absorber, preferably 0.5 to 3% (m/m), so as to reduce or avoid skin irritation.Type: ApplicationFiled: May 2, 2006Publication date: November 2, 2006Inventors: Thomas Langguth, Stefan Bracht
-
Publication number: 20050142175Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2005Inventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk